ACCG-2671
Low EvidenceAn oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection.
What It Is
ACCG-2671 is an investigational oral, once-daily small molecule that activates the amylin receptor, being developed by Structure Therapeutics for the treatment of obesity. Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying; amylin-based drugs (such as the injectable cagrilintide, eloralintide, and petrelintide) have emerged as one of the most promising non-incretin approaches to weight loss, valued for strong appetite control and the potential to preserve lean mass better than some GLP-1 regimens. Most amylin agonists are injectable peptides. ACCG-2671 is notable because it is a small molecule designed to be taken as a daily pill, created with Structure Therapeutics' structure-based drug-discovery platform to reproduce amylin biology orally. The company selected ACCG-2671 as its lead oral amylin candidate in December 2024 and announced the start of a first-in-human Phase 1 study in December 2025. That study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamic activity in both healthy volunteers and people with obesity, using single-ascending-dose and multiple-ascending-dose cohorts. In preclinical work the company reported potent target engagement, robust weight loss as a standalone treatment and additional weight loss when combined with a GLP-1 receptor agonist, a favorable safety profile, and pharmacokinetics suitable for once-daily dosing. ACCG-2671 has no published human efficacy data yet, is not approved by any regulator, is not a marketed or compounded product, and is not on the FDA's July 2026 PCAC compounding review list. As a brand-new clinical-stage drug candidate, it should be distinguished sharply from the 'research chemical' compounds sold online.
Why Researchers Study It
ACCG-2671 targets one of obesity medicine's most sought-after goals: delivering amylin biology — strong satiety and potential lean-mass advantages — in a convenient once-daily oral small molecule rather than an injectable peptide. Researchers are interested in whether an oral amylin agonist can match the weight loss of injectable amylin peptides, work as a standalone therapy or as an oral combination partner with GLP-1 drugs, and achieve acceptable gastrointestinal tolerability. It represents the next frontier after oral GLP-1 (orforglipron, oral semaglutide): an oral, mechanistically distinct partner that could broaden combination obesity therapy.
Proposed Mechanisms
- Activates the amylin receptor (calcitonin receptor paired with RAMP co-receptors) as a small-molecule agonist
- Promotes satiety and reduces food intake through central amylin signaling
- Slows gastric emptying to prolong post-meal fullness
- Designed for oral, once-daily dosing rather than injection
- Intended to act as a standalone agent or as an oral combination partner with GLP-1 receptor agonists
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (Phase 1, ongoing) | First-in-human single- and multiple-ascending-dose study in healthy volunteers and adults with obesity (initiated Dec 2025) | Evaluating safety, tolerability, pharmacokinetics, and pharmacodynamic activity; no results published yet | Source |
| Preclinical (developer-reported) | Animal models of obesity, monotherapy and combination with a GLP-1 receptor agonist | Reported potent target engagement, robust weight loss alone and added weight loss in combination with a GLP-1 RA, favorable safety, and once-daily oral pharmacokinetics | Source |
Commonly Discussed Benefits
Researching ACCG-2671? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- No human efficacy or safety data have been published — a first-in-human Phase 1 study only began in December 2025
- Not approved by the FDA or any regulator; not a marketed, prescribed, or compounded product
- Not on the FDA's July 2026 PCAC compounding review list and not legitimately available to consumers
- All weight-loss and safety claims so far come from preclinical (animal) data reported by the developer
- It is a small molecule, not a peptide, despite targeting the same amylin receptor as injectable amylin peptides
- Most experimental amylin agonists cause gastrointestinal side effects (nausea, vomiting); the oral tolerability of ACCG-2671 in humans is not yet known
Comparisons
See how ACCG-2671 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Structure Therapeutics — Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 (Dec 17, 2025) PubMed
- [2] Structure Therapeutics — Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 (Dec 17, 2024) PubMed
- [3] Structure Therapeutics — ACCG-2671 Phase 1 initiation (investor relations) PubMed
Keep researching in the app
- Log ACCG-2671 to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Cagrilintide
High EvidenceA long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.
Eloralintide
Medium EvidenceA selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2.
Amycretin
Medium EvidenceA unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a.
Petrelintide
Medium EvidenceA long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo.